Navigation Links
NYSE Amex Required Update
Date:8/29/2011

or reductions or elimination of U.S. government funding for one or more of the Company's development programs, the award of government contracts to our competitors, unforeseen safety issues, unexpected determinations that these product candidates prove not to be effective and/or capable of being marketed as products, as well as risks detailed from time to time in PharmAthene's Form 10-K under the caption "Risk Factors" and in its other reports filed with the U.S. Securities and Exchange Commission (the "SEC"). In particular, the timing of the Court's decision and outcome of the case are uncertain. The Court could rule against the Company and find that SIGA did not breach. Furthermore, even if the Court rules in our favor, there can be no assurance that the associated remedy will be significant. Copies of PharmAthene's public disclosure filings are available from its investor relations department and our website under the investor relations tab at http://www.pharmathene.com.


'/>"/>
SOURCE PharmAthene, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Safety in Drinking Water? Monitoring for Radioactive Contaminants Only Required Every Three, Six, or Nine Years per Federal Law
2. BioNeutrals Ygiene(TM) Hospital Grade Achieves a 100% Total Kill (Pass) Against the Life Threatening Clostridium Difficile (C.diff) Spores in Independent EPA Required Protocol Testing.
3. Tengion Provides Business Update and Reports Second Quarter 2011 Financial Results
4. Lexicon to Provide Clinical Pipeline Update and Report Second Quarter 2011 Financial Results
5. BioMarin Provides Update on GALNS Phase 1/2 Extension Study (MOR-100)
6. Medicare HIT Incentive Update for the Oncology Practice - Free Educational Webinar
7. MIT research update: New way to store suns heat
8. Nile Therapeutics Provides Update on Ongoing Phase I Clinical Trial of Cenderitide
9. China-Biotics Provides Update
10. Auxilium Pharmaceuticals, Inc. Updates Launch Progress of XIAPEX® in EU
11. Tengion Provides Business Update and Reports First Quarter 2011 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2013)... Senomyx , Inc. (NASDAQ: ... to discover, develop, and commercialize novel flavor ingredients, announced ... the Company,s Vice President, Biology and Gwen ... Communications, will present an overview of Senomyx,s technology and ... Time (7:25 a.m. Pacific Time) during the Citi 2013 ...
(Date:5/24/2013)... 24, 2013 Many factors impact tissues ... or efflux transporters at the blood-tissue barrier. Even when ... unbound fractions in the tissue rather than the total ... challenges is required to guide lead optimization, predict in ... species-dependent variables that may impact the likely human clinical ...
(Date:5/24/2013)... Vestiage, Inc. (stock symbol "VEST") a publicly ... and development, sales and marketing of premium branded ... that it is awarding exclusive Vestiage territories in ... Skin Illuminating Facial Care. Qualified applicants can request ... email to info(at)vestiageinc(dot)com and putting RELUMA in the ...
(Date:5/23/2013)... CAMBRIDGE, England , May 24, 2013 ... von Mundipharma angefertigt – Bei der ... Version , 91 % der Teilnehmer einer ... obwohl nur 20 % laut GINA [*] -Definition [1] ... zeigt, dass Menschen mit Asthma generell einer von vier ...
Breaking Biology Technology:SENOMYX TO WEBCAST CORPORATE PRESENTATION AT THE CITI 2013 GLOBAL CONSUMER CONFERENCE 2DMPK for Targeted Tissue Delivery: Solutions for the Most Challenging Part of Outsourcing, New Life Science Webinar Hosted by Xtalks 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 2Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 3Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 4Vestiage Announces Launch of Exclusive Territories for Reluma Brand Sales in USA 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 2Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 3Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 4Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 5Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 6Neue Forschungsergebnisse zeigen Verbindung zwischen suboptimaler Asthmaversorgung und Patienteneinstellungen in Europa auf 7
... Ohio, June 22, 2011 With the intent to ... disease in Akron, the Austen BioInnovation Institute in Akron ... the conference "Healthier by Design: Creating Accountable Care Communities" ... regional health and wellness thought-leaders, the strategic discussion is ...
... Colorado Institute for Drug, Device and Diagnostic Development ... the Colorado life science ecosystem through company creation ... Veterinary Emerging Technologies Development Corporation (VetDC) to receive ... commercializes technologies to address serious unmet medical needs ...
... 2011 VENENUM Biodesign, a drug discovery company that ... to identify potential therapeutic agents against its novel disease-based ... opened its new medicinal chemistry space at 8 Black ... facility comprises over 11,000 square feet of state-of-the-art research ...
Cached Biology Technology:Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 2Austen BioInnovation Institute in Akron Begins Work on Roadmap for First U.S. Accountable Care Community 3Colorado Institute for Drug, Device and Diagnostic Development Awards Funding to Fort Collins-based VetDC 2VENENUM Biodesign Announces Opening of Medicinal Chemistry Labs 2
(Date:5/23/2013)... and fastest growing open-access publishers, announces the launch ... and Biotechnology . , A broad scope ... and Biotechnology will provide a single open-access ... research to be disseminated and discussed. , ... provide an open-science and interactive web platform for ...
(Date:5/23/2013)... when microbial pathogens are growing increasingly resistant to the ... of Wisconsin scientists has synthesized a potent new class ... staph infections. , Writing online in the Journal ... by University of Wisconsin-Madison chemistry Professor Helen Blackwell describes ... of Staphylococcus aureus , a bacterium at the ...
(Date:5/22/2013)... investigators also conclude that the 20 percent reduction ... (LDCT) versus chest X-ray (CXR) screening previously reported ... experienced screening centers in the United States. , ... their patients about the benefits and risks of ... the New England Journal of Medicine ...
Breaking Biology News(10 mins):Frontiers launches new open-access journal in Bioengineering and Biotechnology 2University of Wisconsin chemists find new compounds to curb staph infection 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 2NLST: CT detects twice as many lung cancers as X-ray at initial screening exam 3
... An ichthyologist from the Wildlife Conservation Society's New York ... fish discovered on the African island nation of Madagascar ... has dedicated much of his career safeguarding Madagascar's little- ... of biologists from the American Museum of Natural History ...
... discovered to their surprise that a drug commonly used ... growth of new blood vessels commonly seen in cancers. ... use, which may fast-track its availability as an antiangiogenesis ... blood vessel growth, treatment with itraconazole reduced blood vessel ...
... As more and more corn grain is diverted to ... shortages. However, ethanol made from cellulosic materials instead of ... according to research by a Michigan State University ethanol ... materials science professor, has used life cycle analysis tools, ...
Cached Biology News:Anti-fungal drug stops blood vessel growth 2With cellulosic ethanol, there is no food vs. fuel debate according to MSU scientist 2
... and M.W. Turner (1997). ... step-by-step methods for the ... molecules, the use of ... analytical probes and as ...
Request Info...
RABBIT ANTI PORCINE CARBOXYPEPTIDASE B...
... Maker, 1. Modular system for large ... up to six lab-cast or precast ... with 18- or 24-cm Immobiline DryStrip ... gel cassettes.Innovative design simplifies loading and ...
Biology Products: